These targeted drugs approved by the U.S. Food and Drug Administration (FDA) for clinical immunotherapy of TC can be categorized into two parts: receptor tyrosine kinase inhibitors, which can block tumor growth signals, and tropomyosin receptor kinase inhibitors, which can block proteins required for cell growth. Here, NTRK1 is linked to neoplasm.